Bargain hunters should continue to avoid HEXO's stock.
HEXO's preliminary revenue figures for its fiscal fourth quarter aren't sitting well with investors today.
Which of these top pot stocks is the better buy right now?
Which of these two biotech titans is the better buy right now?
These three beaten-down cancer stocks could prove to be amazing value plays.
A short-seller report weighed on the Chinese biotech's shares last month.
AbbVie's shares reversed course last month. Here's why.
The competitive outlook for a key therapy is worrying investors.
Which of these pot titans is the better buy?
Aphria and Charlotte's Web Holdings are both outstanding long-term growth vehicles. Here's why.
AbbVie and Amgen are two great stocks that are way too cheap right now.
These small-cap healthcare stocks are definitely worth checking out this month.
Geron announced an important regulatory win today.
These two top pot stocks will probably continue to struggle in the fourth quarter.
The market isn't pleased with its latest clinical update.
These two penny marijuana stocks may be worth adding to your portfolio right now.
AbbVie and Eli Lilly have both stumbled this year. Which of these top pharma stocks is better positioned for a rebound?
Here's why Catalyst's shareholder might want to simply shrug off yesterday's downturn.
Catalyst's latest bout of volatility could be a great buying opportunity for risk-tolerant investors.
A bet on this Canadian marijuana company is a bet on the political future of the country south of its home market.